Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Ventoclax: A Phase II Study
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Dasatinib (Primary) ; Venetoclax
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Jul 2018 Planned number of patients changed from 100 to 140.
- 18 Jul 2018 Status changed from active, no longer recruiting to recruiting.